Valuation Watch: Bargain Prices Not Enough to Flood PIPEs
This article was originally published in Start Up
Executive Summary
Although public biotechs are cheap, low prices alone are not enough to drive venture investments in public equity. VCs are looking for companies with attractive assets, especially candidates in later stages.